Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24127683 | 0.89 | ADRA1A (0.36) | KDM4EMEN1NPC1ALDH1A1TP53 | |
| SCHEMBL20907118 | 0.87 | NPY1R (0.35) | KDM4EMEN1NPC1ALDH1A1TP53 | |
| SCHEMBL20906913 | 0.87 | NPY1R (0.35) | KDM4EMEN1NPC1ALDH1A1TP53 | |
| SCHEMBL1539510 | 0.87 | KDM4E (0.38) | KDM4EMEN1NPC1ALDH1A1TP53 | |
| SCHEMBL30238446 | 0.87 | KDM4E (0.38) | KDM4EMEN1NPC1ALDH1A1TP53 | |
| SCHEMBL20473280 | 0.86 | ALDH1A1 (0.35) | KDM4EMEN1NPC1ALDH1A1TP53 | |
| SCHEMBL19194700 | 0.86 | KDM4E (0.34) | KDM4EMEN1NPC1ALDH1A1TP53 | |
| SCHEMBL19006558 | 0.86 | ALDH1A1 (0.35) | KDM4EMEN1NPC1ALDH1A1TP53 | |
| SCHEMBL19006562 | 0.86 | ADRA1A (0.34) | KDM4EMEN1NPC1ALDH1A1TP53 | |
| SCHEMBL17244393 | 0.86 | KDM4E (0.35) | KDM4EMEN1NPC1ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3553059-B1 | 8-BROMO-1-METHYL-6-(2-PYRIDINYL)-4H-IMIDAZO[1,2-A][1,4]BENZODIAZEPINE-4-PROPANOIC ACID METHYL ESTER (REMIMAZOLAM, CNS 7056) HYDROBROMIDE (1:1) SALT FOR INJECTION FOR SEDATION AND ANESTHESIA | CHENGDU BRILLIANT PHARMACEUTICAL CO LTD (CN) | 2021-10-13 | — | — | EP | disclosed |
| EP-3553059-A1 | HYDROBROMATE OF BENZODIAZEPINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | Chengdu Brilliant Pharmaceutical Co., Ltd. (CN) | 2019-10-16 | — | — | EP | disclosed |
| US-20190308981-A1 | HYDROBROMIDE OF BENZODIAZEPINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | CHENGDU BRILLIANT PHARMACEUTICAL CO., LTD. (CN) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308981-A1 | HYDROBROMIDE OF BENZODIAZEPINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF | GABRA4, GABRA1, GABRA3 | KDM4E 330/4885MEN1 2131/4885NPC1 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.